Vaxcyte, Inc. $PCVX Stock Holdings Lowered by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 9.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 371,550 shares of the company’s stock after selling 39,055 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.25% of Vaxcyte worth $21,598,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. NEXTBio Capital Management LP acquired a new stake in Vaxcyte in the 4th quarter valued at approximately $4,406,000. Norges Bank bought a new position in shares of Vaxcyte in the fourth quarter worth $56,703,000. Elmind Capital LP bought a new position in shares of Vaxcyte in the fourth quarter worth $13,450,000. Eventide Asset Management LLC increased its holdings in shares of Vaxcyte by 141.8% during the fourth quarter. Eventide Asset Management LLC now owns 917,115 shares of the company’s stock valued at $42,313,000 after purchasing an additional 537,785 shares during the period. Finally, Candriam S.C.A. bought a new stake in shares of Vaxcyte during the first quarter valued at about $18,306,000. 96.78% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Vaxcyte

In other news, COO Jim Wassil sold 3,477 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $61.07, for a total transaction of $212,340.39. Following the completion of the transaction, the chief operating officer owned 155,041 shares in the company, valued at approximately $9,468,353.87. This trade represents a 2.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Harpreet Dhaliwal sold 17,000 shares of Vaxcyte stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $55.00, for a total transaction of $935,000.00. Following the completion of the transaction, the insider directly owned 76,756 shares in the company, valued at $4,221,580. This represents a 18.13% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 121,873 shares of company stock valued at $6,671,730 over the last 90 days. Insiders own 3.30% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on PCVX shares. Wall Street Zen raised shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Zacks Research upgraded shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $86.00.

Vaxcyte Stock Performance

PCVX opened at $61.16 on Friday. The company has a market capitalization of $9.10 billion, a PE ratio of -8.02 and a beta of 1.22. The stock’s fifty day moving average is $58.22 and its 200-day moving average is $56.20. Vaxcyte, Inc. has a one year low of $30.81 and a one year high of $65.00.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($2.06) by $0.09. During the same period in the prior year, the firm posted ($1.22) EPS. On average, equities research analysts forecast that Vaxcyte, Inc. will post -7.6 EPS for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.